MAIA RSI Chart
Last 7 days
8.9%
Last 30 days
18.2%
Last 90 days
89.0%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 25, 2024 | smith stan | bought | 299,409 | 2.03 | 147,492 | - |
Apr 25, 2024 | louie ngar yee | bought | 39,919 | 2.03 | 19,665 | - |
Mar 14, 2024 | luput cristian | bought | 81,059 | 1.17 | 69,282 | - |
Mar 14, 2024 | louie ngar yee | bought | 200,000 | 1.17 | 170,940 | - |
Mar 14, 2024 | guerrero ramiro | bought | 8,105 | 1.17 | 6,928 | - |
Mar 14, 2024 | chaouki steven m | bought | 40,530 | 1.17 | 34,641 | - |
Mar 14, 2024 | smith stan | bought | 200,000 | 1.17 | 170,940 | - |
May 18, 2023 | guerrero ramiro | bought | 2,964 | 2.47 | 1,200 | - |
May 15, 2023 | luput cristian | bought | 7,890 | 2.63 | 3,000 | - |
Apr 28, 2023 | vitoc vlad | bought | 10,000 | 2.5 | 4,000 | chief executive officer |
Which funds bought or sold MAIA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 01, 2024 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | sold off | - | - | - | -% |
May 01, 2024 | Centric Wealth Management | unchanged | - | 100,125 | 196,890 | 0.06% |
Apr 18, 2024 | Naviter Wealth, LLC | unchanged | - | 22,833 | 48,770 | 0.01% |
Apr 15, 2024 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | added | 8.11 | 17,884 | 35,200 | -% |
Apr 15, 2024 | Sunbelt Securities, Inc. | reduced | -33.33 | 44.00 | 220 | -% |
Apr 15, 2024 | Brookstone Capital Management | sold off | -100 | -14,810 | - | -% |
Apr 09, 2024 | MATHER GROUP, LLC. | new | - | 28.00 | 28.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 86.27 | -1,934 | 203,766 | -% |
Feb 14, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | added | 46.71 | -24,951 | 88,569 | -% |
Feb 14, 2024 | STATE STREET CORP | new | - | 24,921 | 24,921 | -% |
Peers (Alternatives to MAIA Biotechnology, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.6B | 6.8B | -9.03 | 6.22 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.9B | 1.8B | -42.88 | 10.32 | ||||
BMRN | 15.8B | 2.5B | 76.99 | 6.4 | ||||
INCY | 11.9B | 3.8B | 15.95 | 3.16 | ||||
MID-CAP | ||||||||
APLS | 5.6B | 396.6M | -10.5 | 14 | ||||
BBIO | 4.8B | - | -7.28 | 60.35 | ||||
AXSM | 3.5B | 270.6M | -14.83 | 13.11 | ||||
ARWR | 2.9B | 240.7M | -9.67 | 12.18 | ||||
ACAD | 2.8B | 726.4M | -45.84 | 3.87 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.07 | 4.5 | ||||
NVAX | 652.2M | 983.7M | -1.2 | 0.66 | ||||
CRBP | 390.9M | 881.7K | -8.76 | 466.16 | ||||
INO | 270.2M | 4.9M | -2 | 55.51 | ||||
IBIO | 6.4M | 2.1M | -0.24 | 2.14 |
MAIA Biotechnology, Inc. News
Balance Sheet | |||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | 8.1% | 7,567 | 7,001 | 10,269 | 9,074 | 12,022 | 14,783 | 9,760 | 10,543 | 11,327 | 747 |
Current Assets | 14.0% | 7,564 | 6,633 | 9,776 | 8,334 | 11,808 | 14,780 | 8,610 | - | 10,672 | 747 |
Cash Equivalents | 17.1% | 7,151 | 6,105 | 9,146 | 7,586 | 10,951 | 14,064 | 8,150 | 10,293 | 10,574 | 663 |
Liabilities | 66.7% | 7,089 | 4,253 | 3,394 | 3,991 | 3,514 | 2,672 | 3,098 | 2,622 | 2,146 | 2,363 |
Current Liabilities | 19.0% | 4,937 | 4,150 | 3,273 | 3,766 | 3,269 | 2,456 | 3,098 | - | 2,146 | 1,694 |
Shareholder's Equity | -82.6% | 478 | 2,748 | 6,874 | 5,083 | 8,508 | 12,111 | 6,662 | 9,014 | 9,181 | - |
Retained Earnings | -10.8% | -63,980 | -57,723 | -52,847 | -48,324 | -44,207 | -40,061 | -35,157 | - | -28,437 | -15,934 |
Additional Paid-In Capital | 6.5% | 64,472 | 60,514 | 59,747 | 53,432 | 52,730 | 52,223 | 41,823 | - | 37,618 | 12,600 |
Shares Outstanding | 23.4% | 16,986 | 13,761 | 13,648 | 10,996 | 10,956 | 8,714 | 8,197 | 7,752 | 7,585 | 4,434 |
Float | - | - | - | 22,484 | - | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Cashflow From Operations | -26.5% | -3,992 | -3,157 | -2,560 | -3,360 | -2,949 | -4,319 | -2,019 | -2,807 | -1,607 | -1,311 | - | - |
Share Based Compensation | 138.6% | 1,362 | 571 | 619 | 538 | 489 | 532 | 585 | 713 | 614 | 779 | - | - |
Cashflow From Financing | 3890.3% | 5,025 | 126 | - | - | -192 | 10,259 | -120 | 2,531 | 1,229 | 5,483 | - | - |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Operating expenses: | ||
Research and development expenses | $ 11,112,257 | $ 8,933,314 |
General and administrative expenses | 9,070,124 | 6,143,527 |
Ratchet share expense | 1,099,360 | |
Total operating expenses | 20,182,381 | 16,176,201 |
Loss from operations | (20,182,381) | (16,176,201) |
Other income (expense): | ||
Interest expense | (6,863) | (6,967) |
Interest income | 34,490 | 1,870 |
Australian research and development incentives | 176,719 | 313,625 |
Change in fair value of warrant liability | 205,130 | 98,394 |
Other income (expense), net | 409,476 | 406,922 |
Net loss | (19,772,905) | (15,769,279) |
Deemed dividend on warrant modification | (450,578) | |
Net loss attributable to MAIA Biotechnology, Inc. shareholders | $ (19,772,905) | $ (16,219,857) |
Net loss per share | ||
Net loss per share basic | $ (1.49) | $ (1.75) |
Net loss per share diluted | $ (1.49) | $ (1.75) |
Weighted average common shares outstanding basic | 13,261,572 | 9,276,761 |
Weighted average common shares outstanding diluted | 13,261,572 | 9,276,761 |
Consolidated Balance Sheets - USD ($) | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash | $ 7,150,695 | $ 10,950,927 |
Prepaid expenses and other current assets | 268,677 | 554,321 |
Australia research and development incentives receivable | 144,680 | 302,789 |
Total current assets | 7,564,052 | 11,808,037 |
Deferred offering costs | 0 | 211,203 |
Other assets | 2,800 | 2,800 |
Total assets | 7,566,852 | 12,022,040 |
Current liabilities: | ||
Accounts payable | 1,638,546 | 1,165,505 |
Accrued expenses | 3,298,607 | 2,103,401 |
Total current liabilities | 4,937,153 | 3,268,906 |
Long term liabilities: | ||
Warrant liability | 2,152,188 | 245,341 |
Total liabilities | 7,089,341 | 3,514,247 |
Commitments and contingencies (Note 7) | ||
Stockholders' equity (deficit) | ||
Preferred stock, $0.0001 par value, 30,000,000 shares authorized at December 31, 2023 and December 31, 2022, 0 shares issued and outstanding | ||
Common stock, $0.0001 par value, 70,000,000 shares authorized at December 31, 2023 and December 31, 2022, 16,986,254 and 10,955,904 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 1,699 | 1,096 |
Additional paid-in capital | 64,472,249 | 52,729,942 |
Accumulated deficit | (63,980,177) | (44,207,272) |
Accumulated other comprehensive loss | (16,260) | (15,973) |
Total stockholders' equity | 477,511 | 8,507,793 |
Total liabilities and stockholders' equity | $ 7,566,852 | $ 12,022,040 |